ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
BioAge Labs Inc

BioAge Labs Inc (BIOA)

4,80
0,33
(7,38%)
Fermé 12 Décembre 10:00PM
4,74
-0,06
( -1,25% )
Avant marché: 2:30PM

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

Dernier
4,74
Prix Achat
4,64
Prix Vente
4,74
Volume échangé
7 701
0,00 Fourchette du Jour 0,00
4,23 Plage de 52 semaines 26,62
Cap du marché
Clôture Veille
4,80
Ouverture
-
Dernière Transaction
17
@
4.67
Dernière heure de transaction
14:39:02
Volume financier
-
VWAP
-
Volume moyen (3 m)
602 692
Actions en circulation
35 848 738
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-2,69
Bénéfice par action (BPA)
-1,78
Chiffre d'affairess
-
Bénéfice net
-63,85M

À propos de BioAge Labs Inc

BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights in... BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Azelaprag, our lead product candidate, demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function in preclinical obesity models. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Newark, Delaware, USA
Fondé
-
BioAge Labs Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker BIOA. Le dernier cours de clôture d'BioAge Labs était de US$4,80. Au cours de la dernière année, les actions de BioAge Labs ont été négociées dans une fourchette de prix de US$ 4,23 à US$ 26,62.

BioAge Labs compte actuellement 35 848 738 actions en circulation. La capitalisation boursière d'BioAge Labs est de US$172,07 million. BioAge Labs a un ratio cours/bénéfice (ratio PE) de -2.69.

BIOA Dernières nouvelles

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share...

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

BioAge Labs to Present at Upcoming Investor Conferences

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash...

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as...

BioAge Labs to Present at Jefferies London Healthcare Conference

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic...

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

BioAge Labs Announces Pricing of Upsized Initial Public Offering

RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-13.73-74.336762317318.4720.374.2331510135.7430905CS
4-15.53-76.615688209220.2721.454.239530497.94556338CS
12-17.76-78.933333333322.526.624.2360269213.89826652CS
26-17.76-78.933333333322.526.624.2360269213.89826652CS
52-17.76-78.933333333322.526.624.2360269213.89826652CS
156-17.76-78.933333333322.526.624.2360269213.89826652CS
260-17.76-78.933333333322.526.624.2360269213.89826652CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
PALIPalisade Bio Inc
US$ 2,88
(105,71%)
25,53M
TRVITrevi Therapeutics Inc
US$ 4,62
(85,54%)
11,7M
SYTASiyata Mobile Inc
US$ 0,9631
(28,76%)
19,1M
LAESSEALSQ Corporation
US$ 1,42
(23,48%)
14,58M
ATLNAtlantic International Corporation
US$ 7,00
(22,74%)
134
KROSKeros Therapeutics Inc
US$ 17,80
(-74,07%)
1,4M
SPGCSacks Parente Golf Inc
US$ 0,5416
(-61,31%)
312,32k
AVGRAvinger Inc
US$ 0,4431
(-45,96%)
156,89k
TFFPTFF Pharmaceuticals Inc
US$ 0,0962
(-40,87%)
802,73k
BCTXBriaCell Therapeutics Corporation
US$ 0,6615
(-39,86%)
1,22M
CDTConduit Pharmaceuticals Inc
US$ 0,1059
(19,93%)
49,3M
PALIPalisade Bio Inc
US$ 2,88
(105,71%)
25,54M
SYTASiyata Mobile Inc
US$ 0,9637
(28,84%)
19,1M
AMPGAmplitech Group Inc
US$ 2,25
(16,58%)
15,68M
LAESSEALSQ Corporation
US$ 1,42
(23,48%)
14,61M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock